Small Cell Lung Cancer: Therapies and Targets

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 133-142

  Pillai, Rathi N ^a   Owonikoko, Taofeek K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84894412235     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.015     Document Type: Article

References (98)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. R. Govindan, N. Page, and D. Morgensztern et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 2006 4539 4544
3. T.K. Owonikoko, C.C. Ragin, and C.P. Belani et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results database J Clin Oncol 25 2007 5570 5577
4. M. Zelen Keynote address on biostatistics and data retrieval Cancer Chemother Rep 34 1973 31 42
5. R.A. Stahel, R. Ginsberg, and K. Havemann et al. Staging and prognostic factors in small cell lung cancer: a consensus report Lung Cancer 5 1989 119 126
6. F.A. Shepherd, J. Crowley, and P. Van Houtte et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer J Thorac Oncol 2 2007 1067 1077
7. P. Goldstraw, J. Crowley, and K. Chansky et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714
8. M.B. McIllmurray, R.J. Bibby, and B.E. Taylor et al. Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer Thorax 44 1989 215 219
9. M. Fukuoka, K. Furuse, and N. Saijo et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer J Natl Cancer Inst 83 1991 855 861
10. B.J. Roth, D.H. Johnson, and L.H. Einhorn et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group J Clin Oncol 10 1992 282 291
11. S. Sundstrom, R.M. Bremnes, and S. Kaasa et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up J Clin Oncol 20 2002 4665 4672
12. S. Baka, R. Califano, and R. Ferraldeschi et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer Br J Cancer 99 2008 442 447
13. J.L. Pujol, L. Carestia, and J.P. Daures Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent Br J Cancer 83 2000 8 15
14. D.V. Skarlos, E. Samantas, and P. Kosmidis et al. Randomized comparison of etoposide-cisplatin v etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study Ann Oncol 5 1994 601 607
15. A. Rossi, M. Di Maio, and P. Chiodini et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data J Clin Oncol 30 2012 1692 1698
16. K. Noda, Y. Nishiwaki, and M. Kawahara et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91
17. N. Hanna, P.A. Bunn Jr., and C. Langer et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24 2006 2038 2043
18. P.N. Lara Jr, R. Natale, and J. Crowley et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 27 2009 2530 2535
19. P. Zatloukal, F. Cardenal, and A. Szczesna et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease Ann Oncol 21 2010 1810 1816
20. P.N. Lara Jr, K. Chansky, and T. Shibata et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124 Cancer 116 2010 5710 5715
21. A. Inoue, O. Ishimoto, and S. Fukumoto et al. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405 Ann Oncol 21 2010 800 803
22. Y. Ohe, S. Negoro, and K. Matsui et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer Ann Oncol 16 2005 430 436
23. T.H. Fink, R.M. Huber, and D.F. Heigener et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial J Thorac Oncol 7 2012 1432 1439
24. J.R. Eckardt, J. von Pawel, and Z. Papai et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer J Clin Oncol 24 2006 2044 2051
25. Y. Sun, Y. Cheng, and X. Hao et al. Result of phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small cell lung cancer J Clin Oncol 31 2013 abstract 7507
26. J.D. Hainsworth, L.H. Morrissey, and D.C. Scullin Jr et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network Cancer 94 2002 2426 2433
27. M. Reck, J. von Pawel, and H.N. Macha et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer J Natl Cancer Inst 95 2003 1118 1127
28. P. Lorigan, P.J. Woll, and M.E. O'Brien et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer J Natl Cancer Inst 97 2005 666 674
29. S. Leyvraz, S. Pampallona, and G. Martinelli et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial J Natl Cancer Inst 100 2008 533 541
30. A. Dowlati, L. Crosby, and S.C. Remick et al. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer - the use of complete response rate as the primary endpoint in phase II trials Lung Cancer 32 2001 155 162
31. D. Mavroudis, E. Papadakis, and M. Veslemes et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer Ann Oncol 12 2001 463 470
32. W.P. Steward, J. von Pawel, and U. Gatzemeier et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients J Clin Oncol 16 1998 642 650
33. S. Fetscher, W. Brugger, and R. Engelhardt et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer AnnOncol 8 1997 49 56
34. N. Thatcher, D.J. Girling, and P. Hopwood et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party J Clin Oncol 18 2000 395 404
35. J.H. Schiller, S. Adak, and D. Cella et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group J Clin Oncol 19 2001 2114 2122
36. K.J. Pandya, S. Dahlberg, and M. Hidalgo et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) J Thorac Oncol 2 2007 1036 1041
37. J.Y. Han, H.T. Kim, and K.Y. Lim et al. Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer J Thorac Oncol 3 2008 1039 1045
38. A. Rossi, M.C. Garassino, and M. Cinquini et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis Lung Cancer 70 2010 119 128
39. P.E. Postmus, H.H. Berendsen, and N. van Zandwijk et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy Eur J Cancer Clin Oncol 23 1987 1409 1411
40. M.C. Garassino, V. Torri, and G. Michetti et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis Lung Cancer 72 2011 378 383
41. G. Giaccone, P. Ferrati, and M. Donadio et al. Reinduction chemotherapy in small cell lung cancer Eur J Cancer Clin Oncol 23 1987 1697 1699
42. D.H. Johnson, F.A. Greco, and J. Strupp et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial J Clin Oncol 8 1990 1613 1617
43. G. Giaccone, M. Donadio, and G. Bonardi et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy J Clin Oncol 6 1988 1264 1270
44. T.K. Owonikoko, M. Behera, and Z. Chen et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer J Thorac Oncol 7 2012 866 872
45. J. von Pawel, J.H. Schiller, and F.A. Shepherd et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 1999 658 667
46. M.E. O'Brien, T.E. Ciuleanu, and H. Tsekov et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 24 2006 5441 5447
47. A. Inoue, S. Sugawara, and K. Yamazaki et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 26 2008 5401 5406
48. R. Jotte, J. von Pawel, and D.R. Spigel et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC) J Clin Oncol 29 2011 abstract 7000
49. S. Cheng, W.K. Evans, and D. Stys-Norman et al. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline J Thorac Oncol 2 2007 348 354
50. J. Treat, J. Schiller, and E. Quoix et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results Eur J Cancer 38 Suppl 8 2002 S13 S18
51. J.R. Eckardt, D.L. Bentsion, and O.N. Lipatov et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer J Clin Oncol 27 2009 2046 2051
52. C.K. Rhee, S.H. Lee, and J.S. Kim et al. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer Lung Cancer 72 2011 64 67
53. J. Jeong, B.C. Cho, and J.H. Sohn et al. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial Lung Cancer 70 2010 77 81
54. G.M. Kim, Y.S. Kim, and Y. Ae Kang et al. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients J Thorac Oncol 7 2012 731 736
55. A. Schmittel, M. Knodler, and P. Hortig et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients Lung Cancer 55 2007 109 113
56. J.P. Pignon, R. Arriagada, and D.C. Ihde et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer N Engl J Med 327 1992 1618 1624
57. P. Warde, and D. Payne Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis J Clin Oncol 10 1992 890 895
58. M. Takada, M. Fukuoka, and M. Kawahara et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 J Clin Oncol 20 2002 3054 3060
59. D.B. Fried, D.E. Morris, and C. Poole et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer J Clin Oncol 22 2004 4837 4845
60. D. De Ruysscher, M. Pijls-Johannesma, and S.M. Bentzen et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer J Clin Oncol 24 2006 1057 1063
61. A.T. Turrisi 3rd, K. Kim, and R. Blum et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 340 1999 265 271
62. A. Auperin, R. Arriagada, and J.P. Pignon et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group N Engl J Med 341 1999 476 484
63. S. Patel, O.K. Macdonald, and M. Suntharalingam Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer Cancer 115 2009 842 850
64. B. Slotman, C. Faivre-Finn, and G. Kramer et al. Prophylactic cranial irradiation in extensive small-cell lung cancer N Engl J Med 357 2007 664 672
65. C.M. Rudin, S. Durinck, and E.W. Stawiski et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 44 2012 1111 1116
66. M. Peifer, L. Fernandez-Cuesta, and M.L. Sos et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Nat Genet 44 2012 1104 1110
67. J. Voortman, J.H. Lee, and J.K. Killian et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors Proc Natl Acad Sci U S A 107 2010 13040 13045
68. K. Hibi, T. Takahashi, and Y. Sekido et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer Oncogene 6 1991 2291 2296
69. K. Rygaard, T. Nakamura, and M. Spang-Thomsen Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts Br J Cancer 67 1993 37 46
70. Y. Sekido, Y. Obata, and R. Ueda et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer Cancer Res 51 1991 2416 2419
71. W.L. Wang, M.E. Healy, and M. Sattler et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 Oncogene 19 2000 3521 3528
72. G.W. Krystal, S. Honsawek, and J. Litz et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth Clin Cancer Res 6 2000 3319 3326
73. B.E. Johnson, T. Fischer, and B. Fischer et al. Phase II study of imatinib in patients with small cell lung cancer Clin Cancer Res 9 2003 5880 5887
74. L.M. Krug, J.P. Crapanzano, and C.G. Azzoli et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial Cancer 103 2005 2128 2131
75. G.K. Dy, A.A. Miller, and S.J. Mandrekar et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann Oncol 16 2005 1811 1816
76. H.Y. Lu, G. Zhang, and Q.Y. Cheng et al. Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer Oncol Lett 4 2012 89 93
77. L. Horn, S.E. Dahlberg, and A.B. Sandler et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501 J Clin Oncol 27 2009 6006 6011
78. D.R. Spigel, F.A. Greco, and J.D. Zubkus et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer J Thorac Oncol 4 2009 1555 1560
79. D.R. Spigel, P.M. Townley, and D.M. Waterhouse et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial J Clin Oncol 29 2011 2215 2222
80. S.M. Lee, P.J. Woll, and R. Rudd et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial J Natl Cancer Inst 101 2009 1049 1057
81. S.S. Ramalingam, C.P. Belani, and P.C. Mack et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097) J Thorac Oncol 5 2010 1279 1284
82. R.P. Chowdry, G. Sica, and Z. Chen et al. Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors J Clin Oncol 30 suppl 2012 abstract 7097
83. K. Stefanaki, D. Rontogiannis, and C. Vamvouka et al. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas Anticancer Res 18 1998 1689 1695
84. C.M. Rudin, R. Salgia, and X. Wang et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103 J Clin Oncol 26 2008 870 876
85. M.Q. Baggstrom, Y. Qi, and M. Koczywas et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer J Thorac Oncol 6 2011 1757 1760
86. P.K. Paik, C.M. Rudin, and M.C. Pietanza et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer Lung Cancer 74 2011 481 485
87. C.M. Rudin, C.L. Hann, and E.B. Garon et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin Cancer Res 18 2012 3163 3169
88. L. Gandhi, D.R. Camidge, and M. Ribeiro de Oliveira et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors J Clin Oncol 29 2011 909 916
89. V. Velcheti, and R. Govindan Hedgehog signaling pathway and lung cancer J Thorac Oncol 2 2007 7 10
90. C.P. Belani, S.E. Dahlberg, and C.M. Rudin et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508) J Clin Oncol 2013 31 abstract 7508
91. T.K. Owonikoko, G. Zhang, and P. Yue et al. Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC) Cancer Res 73 8 suppl 2013 abstract 3282
92. T.K. Owonikoko, G. Zhang, and P. Yue et al. Preclinical evaluation of poly (ADP) ribose polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC) Cancer Res 71 8 suppl 2011 abstract 2567
93. R.J. Cardnell, Y. Feng, and L. Diao et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer Clin Cancer Res 19 2013 6322 6328
94. L.A. Byers, J. Wang, and M.B. Nilsson et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 Cancer Discov 2 2012 798 811
95. L. Byers, L. Horn, and J. Gandhi et al. A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE) Cancer Res 2013 73 abstract 2095
96. J.R. Molina, S.J. Mandrekar, and G.K. Dy et al. A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study J Clin Oncol 2013 31 abstract 7509
97. M. Reck, I. Bondarenko, and A. Luft et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small- cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
98. J. Von Pawel, S.W. Kim, and D.R. Spigel et al. CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC) J Clin Oncol 2013 31 abstract TPS7608